To investigate the mechanism of action of the placental angiogenic hormone proliferin (PLF), we analyzed the signaling components in endothelial cells that are required for PLF-induced chemotaxis. Pertussis toxin, which inactivates G i proteins, inhibited PLF-induced chemotaxis of endothelial cells. G i proteins can lead to activation of the mitogen-activated protein kinase (MAPK) pathway; PLF was found to stimulate MAPK activity, and this induction was blocked by both pertussis toxin and a specific inhibitor of MAPK kinase, PD 098059. Furthermore, a blockade of MAPK activation prevented endothelial cell movement in response to PLF. As PLF functionally interacts with the insulin-like growth factor II (IGF-II)/mannose 6-phosphate receptor, we also examined the effects of pertussis toxin and PD 098059 on another ligand for this receptor, a mutant form of IGF-II; both inhibitors also block the action of this factor on endothelial cells. These data suggest that chemotaxis initiated by PLF and mediated by the IGF-II/mannose 6-phosphate receptor occurs through a G protein-coupled pathway, and that MAPK activation is necessary for the chemotactic response. (Endocrinology 138: [2835][2836][2837][2838][2839][2840] 1997) 
dothelial cell movement in response to PLF. As PLF functionally interacts with the insulin-like growth factor II (IGF-II)/mannose 6-phosphate receptor, we also examined the effects of pertussis toxin and PD 098059 on another ligand for this receptor, a mutant form of IGF-II; both inhibitors also block the action of this factor on endothelial cells. These data suggest that chemotaxis initiated by PLF and mediated by the IGF-II/mannose 6-phosphate receptor occurs through a G protein-coupled pathway, and that MAPK activation is necessary for the chemotactic response. (Endocrinology 138: [2835] [2836] [2837] [2838] [2839] [2840] 1997) A NGIOGENESIS, the growth of blood vessels from existing vessels, is essential for normal reproduction and development and is also involved in processes such as wound healing, tumor growth, and metastasis (1) . Angiogenesis is tightly controlled by a number of positive and negative regulators (2) , including the mouse placental hormones proliferin (PLF) and PLF-related protein (3) . PLF, also referred to as mitogen-regulated protein (4) , is a member of the PRL/GH family in the mouse (5) that is expressed specifically in the giant trophoblast cells of the mouse placenta, reaching peak levels at midgestation (6) . PLF stimulates neovascularization in vivo and endothelial cell chemotaxis in culture; based on the chemotaxis assay, PLF represents the major angiogenic activity secreted by the midgestation mouse placenta (3) . PLF binds to endothelial cells in the mouse placenta and is thus likely to be involved in the development of the placental vasculature (3) .
The intracellular signaling pathways used by PLF are unknown. PLF binds to the insulin-like growth factor II (IGF-II)/mannose 6-phosphate (M6P) receptor (7) , and interaction with this receptor is necessary for PLF-induced angiogenesis (8) . The ability of the IGF-II/M6P receptor to function in signal transduction is controversial, though, as the cytoplasmic domain of this receptor lacks any known enzymatic activity. The mitogenic activity of IGF-II has generally been attributed to an interaction with the IGF-I receptor because IGF-II also binds this receptor with high affinity (9, 10), but some effects of IGF-II appear to be mediated through the IGF-II/M6P receptor (11) (12) (13) (14) . Several reports have presented evidence that the IGF-II/M6P receptor can couple to G proteins (15) (16) (17) , although this finding has subsequently been questioned (18) . A mutant form of IGF-II, [Leu 27 ]IGF-II, which binds to the IGF-II/M6P receptor, but not the IGF-I receptor (19, 20) , can induce chemotaxis of rhabdomyosarcoma cells (21) and endothelial cells (8) , but not DNA synthesis (20) , suggesting that one of the specific functions of the IGF-II/M6P receptor is to regulate cell motility.
Both G protein-coupled receptors (22) (23) (24) (25) (26) , including G protein-coupled receptors that mediate chemotaxis (27) (28) (29) , and receptor tyrosine kinases (30) can stimulate the mitogenactivated protein kinase (MAPK) pathway. Activation of MAPK results from its phosphorylation by MAPK kinase (MEK), a process that can be blocked by the specific MEK inhibitor PD 098059 (31) . The pathway from G protein-coupled receptors to MAPK activation involves the G␤␥-dependent phosphorylation of Shc, a key component of the receptor tyrosine kinase-induced protein complex that activates ras, and thus the raf-MEK-MAPK pathway (32, 33) .
Basic fibroblast growth factor (bFGF), a well characterized angiogenic factor that is both chemotactic and mitogenic for endothelial cells (34), is known to induce a pathway leading to the phosphorylation and activation of MAPK (35). In contrast to PLF, bFGF acts by binding to a receptor tyrosine kinase (35, 36). The ability of bFGF to induce endothelial cell mitogenesis can be blocked by the antiangiogenic factor 16K PRL (37), which inhibits bFGF-induced phosphorylation and activation of MAPK (38); these data suggest that MAPK activation is critical in endothelial cells for a mitogenic response to bFGF. Furthermore, Sa and Fox (39) found that bFGF-induced endothelial cell movement, but not mitogenesis, is blocked by pertussis toxin, which ADP-ribosylates G proteins of the G i subclass and renders them inactive (40). Thus, distinct signaling mechanisms appear to be involved in the migratory and proliferative responses of endothelial cells to bFGF.
To characterize the signaling pathways used by PLF in endothelial cells, we have tested the involvement of G proteins and MAPK in PLF-induced chemotaxis.
Materials and Methods

Cell culture and reagents
Primary bovine capillary endothelial cells provided by Dr. J. Folkman (Harvard Medical School, Boston, MA) were propagated in gelatincoated flasks in DMEM (Life Technologies, Grand Island, NY) supplemented with 10% FBS and 100 g/ml endothelial cell mitogen (Biomedical Technologies, Stoughton, MA). Chinese hamster ovary cells expressing PLF-1 (CHO-PLF-1 cells) (7) were propagated in ␣MEM (Life Technologies) supplemented with 10% FBS and 5 g/ml l-proline. The MEK inhibitor PD 098059 has been described previously (31 
Purification of PLF-1
CHO-PLF-1 cells were grown to confluence in T225 tissue culture flasks, washed with PBS, and fed with MCDB 302 (Life Technologies) containing 100 nm CdCl 2 to stimulate transcription of the PLF-1 complementary DNA from the metallothionein gene promoter. The medium was collected and replaced with fresh medium daily for 3-4 days. Collected medium was clarified by centrifugation at 14,000 ϫ g at 4 C, and 2 m ZnSO 4 was added dropwise with stirring to a final concentration of 100 mm. The solution was stirred for 15 min at 4 C, then centrifuged 10 min at 14,000 ϫ g; the pellet was resuspended in 0.5 m EDTA, pH 8.0 (1 ml for every 100 ml starting medium), dialyzed against 100 mm sodium phosphate, pH 8.0, and subjected to a series of chromatographic steps exactly as described by Lee and Nathans (7) to yield purified PLF-1 protein.
Endothelial cell chemotaxis assay
Endothelial cell migration was monitored as described previously (3, 8) . Briefly, cells were incubated overnight in DMEM without serum but with 0.1% BSA, then collected. Test proteins were placed in the bottom well of a Boyden chamber (Neuroprobe, Cabin John, MD), and the chamber was assembled with gelatinized 0.5-m filters (Nucleopore Corp., Pleasanton, CA); the concentrations of PLF, bFGF, and mutant IGF-II required for optimal induction of cell migration have been determined previously (3, 8) . Cells were added to the top chamber (1.3 ϫ 10 4 cells/well). After 6 h at 37 C, the filters were removed, fixed, and stained with Diff-Quik (Baxter Healthcare Corp., McGaw Park, IL), and the number of cells that had migrated to the lower surface of each filter in 10 high power fields was determined. Data were calculated as the mean Ϯ se. To assay the effects of inhibitors, cells were incubated for 30 min at room temperature on a nutator in the presence of pertussis toxin or PD 098059 before loading into the chamber. In experiments using PD 098509, all samples contained 0.5% dimethylsulfoxide (DMSO); this concentration of DMSO was determined to have no effect on cell migration.
MAPK assay
An in vitro kinase assay of immunoprecipitated MAPK was used as previously described (41). Subconfluent 60-mm dishes of endothelial cells were incubated overnight in DMEM without serum. The cells were then treated with test proteins or were first treated for 90 min with pertussis toxin or PD 098059 and then with test proteins. After treatment, the cells were harvested in 0.5 ml ice-cold lysis buffer [50 mm HEPES (pH 7.5), 150 mm NaCl, 5 mm EDTA, 1% Nonidet P-40, 0.5% sodium deoxycholate, 10 mm sodium pyrophosphate, 25 mm ␤-glycerophosphate, 0.5 mm sodium vanadate, 50 mm NaF, 10 g/ml aprotinin, 10 g/ml leupeptin, 1 mm benzamidine, 0.5 mm phenylmethylsulfonyl fluoride, and 1 mm dithiothreitol], and the extracts were clarified by centrifugation. Antibodies against Erk1 and Erk2 (1 g each) were added, and the samples were incubated at 4 C for 2 h on a nutator. Immune complexes were captured with protein A/G agarose, and kinase activity in the immune complexes was assayed in 50 l 50 mm HEPES, 10 mm MgCl 2 , 2 mm EGTA, 1 mm dithiothreitol, 50 m ATP with 100 Ci/ml [␥-
32 P]ATP, and 20 g myelin basic protein. After 10 min at 30 C, SDS sample buffer was added to stop the reaction. Samples were heated at 100 C for 3 min and then centrifuged, and the supernatants were subjected to SDS-PAGE. The amount of phosphorylated myelin basic protein was quantified by analysis of the dried gels on a PhosphorImager (Molecular Dynamics, Sunnyvale, CA). In experiments using PD 098509, all samples contained 0.5% DMSO; this concentration of DMSO was determined to have no effect on MAPK activity in the immune complex assay.
Mitogenesis assay
Endothelial cells were plated in 24-well dishes (1 ϫ 10 4 cells/well) and incubated for 2 days in DMEM without serum but with 0.1% BSA. Cells were treated with mitogen for 8 h, then 1 Ci [ 3 H]thymidine (DuPont-New England Nuclear, Wilmington, DE) was added for 4 -6 h. Cells were washed twice in cold 5% trichloroacetic acid and solubilized in 0.25 n NaOH, and the uptake of the radioactive nucleoside was measured by scintillation counting.
Results
Role of G i in PLF-induced endothelial cell migration
The angiogenic activity of PLF involves an interaction of this hormone with the IGF-II/M6P receptor (8) , which has been implicated in G i protein activation (15) (16) (17) . Initial experiments were, therefore, aimed at determining whether PLF-induced endothelial cell migration involved a G protein intermediate. PLF signaling through G i would also be consistent with the ability of pertussis toxin to block chemotaxis of a number of cell types (42-44). As demonstrated previously (3), addition of PLF to endothelial cells in a Boyden chamber stimulated directed migration (Fig. 1A) . Pertussis toxin caused a dose-dependent decrease in this response, and a concentration of 1 ng/ml pertussis toxin was sufficient to inhibit PLF-induced chemotaxis completely. Basal migration was unaffected by 1 ng/ml pertussis toxin, indicating that this treatment did not affect cell viability.
For comparison, the effect of pertussis toxin was also monitored in bFGF-treated cell cultures, and again, a dose-dependent inhibition of induced migration was observed (Fig.  1A) . Although PLF, by itself, has little or no mitogenic effect on primary bovine capillary endothelial cells (Groskopf, J., and D. Jackson, unpublished observations), bFGF is able to induce DNA synthesis as well as migration in these cell cultures. Pertussis toxin had no effect on the mitogenic activity of bFGF (Fig. 1B) , providing further evidence that the decrease in directed migration could not be attributed to decreased cell viability. These results indicate that PLF-and bFGF-induced chemotaxis (in contrast to bFGF-induced DNA synthesis) involve a G i -dependent step.
PLF-induced activation of MAPK
Another possible component of the PLF signaling pathway leading to chemotaxis is MAPK, as MAPK activation can occur downstream of a pertussis toxin-sensitive G protein (23) (24) (25) (26) (27) (28) (29) . Serum-starved endothelial cells were treated with PLF, and cell lysates were assayed for MAPK activity in an immune complex using myelin basic protein as the substrate. PLF induced MAPK activity within 5 min after treatment, and a peak of MAPK activity (3.5-fold above the level in untreated cells) was detected at approximately 15 min (Fig.  2) . By 30 min, kinase activity had decreased to near-basal levels. Prior incubation of PLF with a monoclonal antibody that blocks PLF-stimulated cell migration (3) also abolished PLF-induced MAPK activation (data not shown). In contrast to these results with PLF, bFGF activated MAPK much more strongly; an increase in MAPK activity was observed within 2.5 min after treatment, peak levels (12-fold) were attained by 10 min, and MAPK activity remained elevated even at 60 min (Fig. 2) .
If PLF stimulation of MAPK occurs through a G i protein, then addition of pertussis toxin to PLF-treated endothelial cells should block an increase in MAPK activity. As predicted, no increase in MAPK activity was detected in lysates from endothelial cells treated with both PLF and pertussis toxin (Fig. 3) . The effect of PD 098059, a specific inhibitor of MEK and, therefore, of MAPK activation (31), was also tested in this assay; PD 098059 was as effective as pertussis toxin in blocking MAPK activation (Fig. 3) . In contrast, only PD 098059 (not pertussis toxin) was able to prevent bFGF-induced MAPK activation, consistent with bFGF stimulation of the MAPK pathway through a G i -independent pathway.
Requirement for MAPK activation in PLF-induced endothelial cell chemotaxis
To determine whether the elevation in MAPK activity in response to PLF is required for a chemotactic response, en- dothelial cells were exposed to the specific MEK inhibitor PD 098059 and then treated with PLF. Similar to the effect of pertussis toxin, PD 098059 inhibited PLF-induced cell migration in a dose-dependent manner (Fig. 4A) . This compound was also effective in blocking bFGF-stimulated migration, although a lower concentration of inhibitor was required to block completely the response to PLF (10 m) than that to bFGF (30 m). These concentrations of inhibitor are similar to those used to block MAPK activation in other cell types (31, 41) . bFGF-induced mitogenesis was also blocked by PD 098059 (Fig. 4B) , consistent with a requirement for MAPK activation in the induction of cell proliferation. Thus, MAPK activation is required for both PLF-and bFGF-induced chemotaxis as well as for bFGF mitogenesis in endothelial cell cultures.
IGF-II stimulation of chemotaxis
As PLF functionally interacts with the IGF-II/M6P receptor, other ligands for this receptor may also induce endothelial cell chemotaxis through a similar signaling pathway.
[Leu 27 ]IGF-II, a mutant form of IGF-II that binds to the IGF-II/M6P receptor but has greatly reduced affinity for the IGF-I receptor (19, 20) , is chemotactic for endothelial cells (8) . Directed migration of endothelial cells in response to [Leu 27 ]IGF-II was effectively prevented by pertussis toxin and PD 098059 (Fig. 5) . These results indicate that binding of either PLF or IGF-II to the IGF-II/M6P receptor on endothelial cells results in the activation of a G i -coupled, MAPKdependent signaling pathway, leading to chemotaxis.
Discussion
The data presented here reveal that endothelial cell chemotaxis induced by PLF as well as by bFGF and IGF-II occurs through a G protein-coupled, MAPK-dependent pathway. A role for pertussis toxin-sensitive G proteins in cell motility has been well established, and we now show that activation of MAPK is necessary for chemotaxis of endothelial cells in response to these factors. As PLF requires an interaction with the IGF-II/M6P receptor to stimulate endothelial cell migration (8), these results suggest that this receptor can couple to a G protein and lead to MAPK activation. The action of pertussis toxin is consistent with reports that G proteins of the G i subclass are specifically activated through the IGF-II/M6P receptor upon binding of IGF-II (16, 17) . Although PLF signaling may involve a receptor complex of which the IGF-II/M6P receptor is only one component, the finding that two ligands, PLF through its M6P moiety and IGF-II, that bind to distinct sites on this receptor (45, 46) each stimulate directed endothelial cell movement through similar pathways strongly argues that this receptor is itself transducing a signal.
The recent discovery of PD 098059 as a specific MEK inhibitor (31) has provided a valuable reagent for investigating the role of MAPK activation in various systems (47, 48) . The high degree of specificity of PD 098059 appears to be due to a specific association with MEK, as this compound does not simply compete with ATP for binding to the kinase (Dudley, D., and A. Saltiel, unpublished results). PD 098059 blocked chemotaxis induced by PLF, providing the first evidence that MAPK activation is absolutely required for the chemotactic response. Consistent with the effect of PD 098059 on chemotaxis, PLF was able to induce MAPK activity in endothelial cells. PLF induced MAPK activity approximately 3.5-fold; this level is similar to that induced by other factors that act as only weak mitogens (49) . The induction of MAPK activity by PLF was blocked by pertussis toxin, indicating that the IGF-II/M6P receptor can activate MAPK only through a G i protein pathway.
Activation of MAPK by bFGF is required for both chemotactic and mitogenic effects. Relative to PLF, bFGF caused a more robust and prolonged induction of MAPK activity, consistent with the ability of bFGF to act as a potent mitogen for these cells. bFGF-induced MAPK activity and DNA synthesis were not sensitive to pertussis toxin, whereas the MEK inhibitor blocked both MAPK activation and DNA synthesis in bFGFtreated cells. The ability of pertussis toxin to prevent bFGFinduced cell migration while having no effect on MAPK activation and mitogenesis, and the ability of the MEK inhibitor to block both MAPK activation and chemotaxis indicate that MAPK activation is a necessary, but insufficient, step for endothelial cell chemotaxis. Thus, the FGF receptor can trigger two signaling pathways in endothelial cells: a G protein-dependent pathway necessary for chemotaxis, and a G proteinindependent pathway leading to MAPK activation and entry of endothelial cells into S phase. These results demonstrate that PLF and bFGF, two angiogenic factors that bind to unrelated receptors, stimulate endothelial cell chemotaxis through similar signaling pathways. 
